Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5984261 | 0.88 | ALDH1A1 (0.30) | ALDH1A1TSHRTDP1 | |
| SCHEMBL6731668 | 0.86 | RXRA (0.32) | ALDH1A1TSHRTDP1 | |
| SCHEMBL6734122 | 0.84 | ALDH1A1 (0.43) | ALDH1A1TSHRTDP1 | |
| SCHEMBL6726973 | 0.79 | BCHE (0.34) | — | |
| SCHEMBL5984227 | 0.78 | GABBR2 (0.34) | ALDH1A1TSHRTDP1 | |
| SCHEMBL6731511 | 0.77 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL6729370 | 0.77 | — | — | |
| SCHEMBL6270579 | 0.76 | ALDH1A1 (0.36) | ALDH1A1TSHRTDP1 | |
| SCHEMBL6727016 | 0.75 | — | — | |
| SCHEMBL5985540 | 0.75 | VCAM1 (0.35) | ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6998419-B2 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. (US) | 2006-02-14 | — | — | US | claimed |
| US-20050215646-A1 | Methods for treating multiple sclerosis and pharmaceutical compositions therefor | RENOVIS, INC. | 2005-09-29 | — | — | US | claimed |
| WO-2005087214-A1 | METHODS FOR TREATING MULTIPLE SCLEROSIS AND PHARMACEUTICAL COMPOSITIONS THEREFOR | RENOVIS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| US-20040198835-A1 | 3,4,5-Trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. | 2004-10-07 | — | — | US | claimed |
| US-20030078297-A1 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. | 2003-04-24 | — | — | US | claimed |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2002-11-07 | — | — | US | claimed |
| US-6342523-B1 | DRUGS AND ANTIINFLAMMATORY AGENTS | CENTAUR PHARMACEUTICALS, INC. | 2002-01-29 | — | — | US | claimed |
| US-6998419-B2 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. (US) | 2006-02-14 | — | — | US | disclosed |
| US-20050215646-A1 | Methods for treating multiple sclerosis and pharmaceutical compositions therefor | RENOVIS, INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005087214-A1 | METHODS FOR TREATING MULTIPLE SCLEROSIS AND PHARMACEUTICAL COMPOSITIONS THEREFOR | RENOVIS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-6835754-B2 | Administering alpha-(4-hydroxy-3,5-di-tert-butylphenyl)-N-tert-octylnitrone for example | RENOVIS, INC. | 2004-12-28 | — | — | US | disclosed |
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040198835-A1 | 3,4,5-Trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. | 2004-10-07 | — | — | US | disclosed |
| US-20030078297-A1 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. | 2003-04-24 | — | — | US | disclosed |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002065993-A2 | USE OF ARYL NITRONE COMPOUNDS IN METHODS FOR TREATING NEUROPATHIC PAIN | CENTAUR PHARMACEUTICALS, INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| CN-1334800-A | 3,4,5-trisubstd. aryl nitrone compounds and pharmaceutical compositions contg. same | CENTAUR PHARMACEUTICALS INC (US) | 2002-02-06 | — | — | CN | disclosed |
| US-6342523-B1 | DRUGS AND ANTIINFLAMMATORY AGENTS | CENTAUR PHARMACEUTICALS, INC. | 2002-01-29 | — | — | US | disclosed |
| EP-1135367-A1 | 3,4,5-TRISUBSTITUTED ARYL NITRONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Centaur Pharmaceuticals, Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032567-A1 | 3,4,5-TRISUBSTITUTED ARYL NITRONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | OPRL1, OPRK1, OPRD1 | ALDH1A1 219/4885TSHR 2366/4885TDP1 814/4885 |
| US-20030078297-A1 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | NOS1, NOS3, CBR1 | ALDH1A1 121/4885TSHR 1520/4885TDP1 693/4885 |
| US-20040198835-A1 | 3,4,5-Trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | NOS1, NOS3, CBR1 | ALDH1A1 114/4885TSHR 1875/4885TDP1 891/4885 |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | OPRL1, OPRD1, OPRK1 | ALDH1A1 200/4885TSHR 3060/4885TDP1 681/4885 |
| US-20050215646-A1 | Methods for treating multiple sclerosis and pharmaceutical compositions therefor | CCL11, TXNRD3, CX3CR1 | ALDH1A1 1148/4885TSHR 2915/4885TDP1 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.